solute carrier family 25 member 22Genealiases: DEE3 · EIEE3 · GC-1 · GC1 · NET44
Q-omics provides the consensus-scored SLC25A22 profile across patient tissues and cancer cell-line models. SLC25A22 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC25A22 is differentially expressed in 18, with the highest sampling consensus in COAD. Additionally, SLC25A22 protein abundance shows 21,102 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where SLC25A22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC25A22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC25A22 survival associations across molecular data types. SLC25A22 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC25A22 RNA expression–survival associations across cancer types. High SLC25A22 expression shows unfavorable associations in KIRC, ACC, LIHC, MESO, UVM and KICH. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC25A22 RNA expression.
This table summarizes SLC25A22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 18, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC25A22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC25A22 shows higher tumor expression in COAD, HNSC, STAD, BLCA, KIRP and LUAD. The COAD box plot shows higher SLC25A22 RNA expression in tumor versus normal tissue (log2 FC = +2.138, t-test p < 0.001).
This table shows molecular features associated with SLC25A22 in patient tissues and cancer cell lines. In patient samples, SLC25A22 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC25A22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
